Hims & Hers Health (HIMS) stock is back in focus as investors react to its push into obesity care through FDA-approved treatments, a Novo Nordisk partnership, and a growing emphasis on peptide based metabolic health.

Recent enthusiasm around obesity care, peptides, and new memberships has come alongside firm short term momentum in Hims & Hers Health stock. The 30 day share price return is 25.63%, yet the 1 year total shareholder return is still down 46.88%, keeping the longer term picture mixed.

If you are comparing Hims & Hers Health with other healthcare names involved in AI and digital medicine, this is a good moment to scan for fresh ideas using the 41 healthcare AI stocks

With Hims & Hers Health stock up 25.63% over the past month but still down 46.88% over the past year, the key question is simple: is this renewed enthusiasm mispricing the risk, or has the market already priced in future growth?

Most Popular Narrative: 81.8% Undervalued

Hims & Hers Health stock closed at $31.47, while the most followed narrative, using a $173.02 fair value estimate, sees a wide gap between price and potential.

Over the long term (10yrs), Hims & Hers has an unusually large addressable market ahead of it. The company’s growth is driven by three reinforcing dimensions:

• Expanding market size, digital healthcare adoption continues to grow globally
• Category expansion, new offerings such as hormonal health, longevity, and sleep
• International scaling, multiple geographies already in the pipeline (e.g. Brazil, Australia)
• Growth inside of the current categories

Want to see why this narrative places such a high fair value on Hims & Hers Health? The core of the thesis sits in aggressive revenue expansion, improving margins, and a profit multiple usually associated with mature compounders. Curious which assumptions on growth, profitability, and future earnings power justify that jump from $31.47 to $173.02?

According to Deep_Insights, the fair value relies on a specific path for revenue growth, profitability and earnings multiples that is very different from what the current share price implies. The narrative leans on accelerating earnings, a sizeable addressable market and a premium future P/E to support that $173.02 figure, which is far above both the recent 1 year share price performance and the current analyst price target of $26.61.

Result: Fair Value of $173.02 (UNDERVALUED)

However, Hims & Hers Health still faces meaningful risks, including execution missteps on new categories like hormone health and labs, or weaker than expected weight loss demand.

Another View: What Hims & Hers Health’s P/S Ratio Signals

The user narrative leans heavily on future earnings power, but current trading tells a different story. Hims & Hers Health is priced at a P/S of 3.1x, which looks expensive against the US Healthcare industry at 1.3x, yet sits below the peer average of 3.7x and a fair ratio estimate of 8.7x.

That wide gap between the 3.1x market price and the 8.7x fair ratio suggests either meaningful upside if sentiment shifts, or a valuation that already carries real execution risk if growth or profitability falls short. Which side of that trade off do you think the current story supports?

Next Steps

Balancing this mix of optimism and concern around Hims & Hers Health comes down to your own tolerance for both risk and potential reward. Move quickly, review the underlying assumptions yourself, and then weigh the 1 key reward and 1 important warning sign highlighted in the 1 key reward and 1 important warning sign

Looking for more investment ideas beyond Hims & Hers Health?

If Hims & Hers Health has your attention, use this momentum as a cue to broaden your watchlist and stress test your portfolio against fresh opportunities.

• Target potential turnarounds by scanning 23 elite penny stocks with strong financials that already show stronger financial footing than many expect from lower priced stocks.
• Focus on quality at a sensible entry point by reviewing the 44 high quality undervalued stocks and see which companies combine solid fundamentals with room for a better rating.
• Prioritise resilience by filtering for companies in the 68 resilient stocks with low risk scores that pair steadier risk profiles with firmer balance sheets and business models.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.